Clinical Trials Cancer Drugs Weight Loss Drugs Monoclonal Antibodies Alzheimer's Disease Cancer Treatment Innovative Therapies Market Competition Oncology Regulatory Affairs
Disruption of AP1M1 extends endosomal retention of antisense drugs, with ongoing tests of its application to broader RNA therapies alongside pathogen interventions.